Cover Image
市場調查報告書

生物醫藥品的全球市場:分析與預測

Global Biopharmaceutical Market Report & Forecast (2016-2021)

出版商 IMARC Services Pvt. Ltd. 商品編碼 367470
出版日期 內容資訊 英文 194 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物醫藥品的全球市場:分析與預測 Global Biopharmaceutical Market Report & Forecast (2016-2021)
出版日期: 2016年07月21日 內容資訊: 英文 194 Pages
簡介

本報告提供全球生物醫藥品的市場相關分析,整體市場規模的成果值、預測值,及各地區、各症狀、各類藥物的詳細趨勢,主要企業簡介與業績,代表性產品的概要與銷售業績、預測,產業整體競爭力 (SWOT分析) 的資訊彙整,為您概述為以下內容。

第1章 市場定義和分析方法

第2章 分析師的見解

第3章 生物醫藥品的概要

第4章 全球生物醫藥品市場:產業趨勢

  • 市場趨勢與預測
    • 到目前為止的業績 (過去8年份)
    • 市場預測 (今後6年份)
  • 各地區的市場區隔
    • 到目前為止的業績 (過去8年份)
    • 市場預測 (今後6年份)
  • 各症狀的市場區隔
    • 自體免疫疾病
    • 腫瘤
    • 代謝障礙
    • 其他
  • 各類藥物的市場區隔
    • 基因改造蛋白質
      • 到目前為止的業績 (過去8年份)
      • 市場預測 (今後6年份)
    • 單株抗體
    • 煉製蛋白質
  • 競爭環境
    • 大生物醫藥品企業
      • Roche
      • Amgen
      • Novo Nordisk
      • AbbVie
      • Sanofi
    • 代表性生物醫藥品
      • Humira
      • Remicade
      • Rituxan
      • Enbrel
      • Lantus

第5章 北美

  • 美國
    • 市場趨勢 (過去8年份)
    • 各類藥物的市場區隔
      • 基因改造蛋白質
      • 單株抗體
      • 煉製蛋白質
    • 大企業的業績
    • 市場預測 (今後6年份)
  • 加拿大

第6章 南美

  • 墨西哥
  • 巴西
  • 阿根廷

第7章 歐洲

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 俄羅斯
  • 土耳其

第8章 亞太地區

  • 日本
  • 中國
  • 澳洲
  • 韓國
  • 印度

第9章 全球生物醫藥品市場:產業分析

目錄
Product Code: SRP00116EM

The global biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today hundreds of biopharmaceuticals have already been approved and many more are in late stages of clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition as out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry's multibillion dollar revenues and strong growth rates in previous years bears a testimony to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors like biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that with their high potency and ability to attack targets beyond the reach of traditional small molecule drugs, biopharmaceuticals provide the industry with a huge scope for future growth. A rich late stage pipeline and increasing demand in emerging markets are also expected to be major drivers in the coming years.

The study covers the market analysis of various segments and sub-segments of the biopharmaceutical industry based on class and key indicative areas. Recombinant proteins currently represent the biggest segment on the basis of class accounting for the majority of the global biopharmaceutical sales. Recombinant proteins are followed by monoclonal antibodies and purified proteins. On the basis of key indicative and therapeutic application areas for biopharmaceuticals, autoimmune diseases represent the largest segment followed by oncology. With most of the current and future monoclonal antibodies targeted against autoimmune diseases such as rheumatoid arthritis and oncology, autoimmune diseases and oncology will continue to represent the dominant indications for biopharmaceuticals over the next five years.

The biopharmaceutical market is largely dominated by the US accounting for nearly half of the total global sales. The other top markets include Germany, Japan, France, Italy, Spain, UK and Canada. Moreover, increasing disposable incomes and a larger access to healthcare insurance, the market for biopharmaceuticals is also expected to expand and offer great opportunities and growth prospects across various emerging markets over the next few years. The report has also provided a robust analysis of the key players operating in the global biopharmaceutical market. Some of the key players analysed in this report include: Roche, Amgen, Novo Nordisk, AbbVie and Sanofi.

IMARC's new report "Global Biopharmaceutical Market Report & Forecast (2016-2021)" gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2021. This report will serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in any form.

What We Have Achieved in this Report?

Deep Qualitative Understanding of Various Factors Driving and Restraining the Global Biopharmaceutical Market

Key Aspects Analyzed:

  • Driving Factors
  • Restraining Factors
  • Market Opportunities
  • Threats

Comprehensive Situation Analysis of the Global Biopharmaceutical Market and its Dynamics

Regions/Countries Covered:

  • North America: United States and Canada
  • Latin America: Mexico, Brazil and Argentina
  • Europe: Germany, France, Italy, Spain, United Kingdom, Russia and Turkey
  • Asia Pacific: Japan, China, Australia, South Korea, India and Indonesia
  • Classes Covered for Each Country: Erythropoietins, Insulin, Interferons, Growth Hormones, Immunoglobulins, Colony Stimulating Factors, Recombinant Blood Factors, Recombinant Enzymes, Growth Factors, Interleukins, Monoclonal Antibodies and Purified Proteins

Focus of the Analysis for Each Country:

  • Total Market Performance
  • Performance of Various Classes
  • Performance of Top Players
  • Market Forecast

Key Questions Answered in this Report:

  • What are the key advantages/ disadvantages of biopharmaceuticals over small molecule drugs in terms of efficacy, safety, price, approval times, market growth, etc.?
  • What are the key opportunities and threats faced by the biopharmaceutical industry?
  • What has been the historical and current performance of the global biopharmaceutical market and how is it expected to perform in the coming years?
  • Which are the world's largest biopharmaceutical markets?
  • Which are the world's fastest growing biopharmaceutical markets?
  • What is the structure and composition of various biopharmaceutical markets across the globe?
  • Which are the world's largest biopharmaceutical segments?
  • Which are the world's fastest growing biopharmaceutical segments?
  • Who are the world's largest biopharmaceutical companies and how have they performed in recent years?

Table of Contents

1. Market Definitions & Research Methodology

2. Analyst Briefing

3. Introduction to Biopharmaceuticals

4. Global Biopharmaceutical Market: Industry Performance

  • 4.1 Market Performance & Forecast
    • 4.1.1 Current Performance (2008-2015)
    • 4.1.2 Market Forecast (2016-2021)
  • 4.2 Market Segmentation by Region
    • 4.2.1 Current Performance (2008-2015)
    • 4.2.2 Market Forecast (2016-2021)
  • 4.3 Market Segmentation by Indication
    • 4.3.1 Autoimmune Diseases
    • 4.3.2 Oncology
    • 4.3.3 Metabolic Disorders
    • 4.3.4 Others
  • 4.4 Market Segmentation by Class
    • 4.4.1 Recombinant Proteins
      • 4.4.1.1 Current Performance (2008-2015)
      • 4.4.1.2 Market Forecast (2016-2021)
    • 4.4.2 Monoclonal Antibodies
      • 4.4.2.1 Current Performance (2008-2015)
      • 4.4.2.2 Market Forecast (2016-2021)
    • 4.4.3 Purified Proteins
      • 4.4.3.1 Current Performance (2008-2015)
      • 4.4.3.2 Market Forecast (2016-2021)
  • 4.5 Competitive Landscape
    • 4.5.1 Top Biopharmaceutical Players
      • 4.5.1.1 Roche
      • 4.5.1.2 Amgen
      • 4.5.1.3 Novo Nordisk
      • 4.5.1.4 AbbVie
      • 4.5.1.5 Sanofi
    • 4.5.2 Top Biopharmaceutical Drugs
      • 4.5.2.1 Humira
      • 4.5.2.2 Remicade
      • 4.5.2.3 Rituxan
      • 4.5.2.4 Enbrel
      • 4.5.2.5 Lantus

5. North America

  • 5.1 US
    • 5.1.1 Market Performance (2008-2015)
    • 5.1.2 Market Segmentation by Class
      • 5.1.2.1 Recombinant Proteins
      • 5.1.2.2 Monoclonal Antibodies
      • 5.1.2.3 Purified Proteins
    • 5.1.3 Performance of Top Players
    • 5.1.4 Market Forecast (2016-2021)
  • 5.2 Canada
    • 5.2.1 Market Performance (2008-2015)
    • 5.2.2 Market Segmentation by Class
      • 5.2.2.1 Recombinant Proteins
      • 5.2.2.2 Monoclonal Antibodies
    • 5.2.3 Performance of Top Players
    • 5.2.4 Market Forecast (2016-2021)

6. Latin America

  • 6.1 Mexico
    • 6.1.1 Market Performance (2008-2015)
    • 6.1.2 Market Segmentation by Class
      • 6.1.2.1 Recombinant Proteins
      • 6.1.2.2 Monoclonal Antibodies
      • 6.1.2.3 Purified Proteins
    • 6.1.3 Performance of Top Players
    • 6.1.4 Market Forecast (2016-2021)
  • 6.2 Brazil
    • 6.2.1 Market Performance (2008-2015)
    • 6.2.2 Market Segmentation by Class
      • 6.2.2.1 Recombinant Proteins
      • 6.2.2.2 Monoclonal Antibodies
      • 6.2.2.3 Purified Proteins
    • 6.2.3 Performance of Top Players
    • 6.2.4 Market Forecast (2016-2021)
  • 6.3 Argentina
    • 6.3.1 Market Performance (2008-2015)
    • 6.3.2 Market Segmentation by Class
      • 6.3.2.1 Recombinant Proteins
      • 6.3.2.2 Monoclonal Antibodies
      • 6.3.2.3 Purified Proteins
    • 6.3.3 Performance of Top Players
    • 6.3.4 Market Forecast (2016-2021)

7. Europe

  • 7.1 Germany
    • 7.1.1 Market Performance (2008-2015)
    • 7.1.2 Market Segmentation by Class
      • 7.1.2.1 Recombinant Proteins
      • 7.1.2.2 Monoclonal Antibodies
      • 7.1.2.3 Purified Proteins
    • 7.1.3 Performance of Top Players
    • 7.1.4 Market Forecast (2016-2021)
  • 7.2 France
    • 7.2.1 Market Performance (2008-2015)
    • 7.2.2 Market Segmentation by Class
      • 7.2.2.1 Recombinant Proteins
      • 7.2.2.2 Monoclonal Antibodies
      • 7.2.2.3 Purified Proteins
    • 7.2.3 Performance of Top Players
    • 7.2.4 Market Forecast (2016-2021)
  • 7.3 Italy
    • 7.3.1 Market Performance (2008-2015)
    • 7.3.2 Market Segmentation by Class
    • 7.3.2.1 Recombinant Proteins
    • 7.3.2.2 Monoclonal Antibodies
    • 7.3.2.3 Purified Proteins
    • 7.3.3 Performance of Top Players
    • 7.3.4 Market Forecast (2016-2021)
  • 7.4 Spain
    • 7.4.1 Market Performance (2008-2015)
    • 7.4.2 Market Segmentation by Class
      • 7.4.2.1 Recombinant Proteins
      • 7.4.2.2 Monoclonal Antibodies
      • 8.4.2.3 Purified Proteins
    • 7.4.3 Performance of Top Players
    • 7.4.4 Market Forecast (2016-2021)
  • 7.5 UK
    • 7.5.1 Market Performance (2008-2015)
    • 7.5.2 Market Segmentation by Class
      • 7.5.2.1 Recombinant Proteins
      • 7.5.2.2 Monoclonal Antibodies
      • 7.5.2.3 Purified Proteins
    • 7.5.3 Performance of Top Players
    • 7.5.4 Market Forecast (2016-2021)
  • 7.6 Russia
    • 7.6.1 Market Performance (2008-2015)
    • 7.6.2 Market Segmentation by Class
      • 7.6.2.1 Recombinant Proteins
      • 7.6.2.2 Monoclonal Antibodies
      • 7.6.2.3 Purified Proteins
    • 7.6.3 Performance of Top Players
    • 7.6.4 Market Forecast(2016-2021)
  • 7.7 Turkey
    • 7.7.1 Market Performance (2008-2015)
    • 7.7.2 Market Segmentation by Class
      • 7.7.2.1 Recombinant Proteins
      • 7.7.2.2 Monoclonal Antibodies
      • 7.7.2.3 Purified Proteins
    • 7.7.3 Performance of Top Players
    • 7.7.4 Market Forecast (2016-2021)

8. Asia Pacific

  • 8.1 Japan
    • 8.1.1 Market Performance (2008-2015)
    • 8.1.2 Market Segmentation by Class
      • 8.1.2.1 Recombinant Proteins
      • 8.1.2.2 Monoclonal Antibodies
      • 8.1.2.3 Purified Proteins
    • 8.1.3 Performance of Top Players
    • 8.1.4 Market Forecast (2016-2021)
  • 8.2 China
    • 8.2.1 Market Performance (2008-2015)
    • 8.2.2 Market Segmentation by Class
      • 8.2.2.1 Recombinant Proteins
      • 8.2.2.2 Monoclonal Antibodies
      • 8.2.2.3 Purified Proteins
    • 8.2.3 Performance of Top Players
    • 8.2.4 Market Forecast (2016-2021)
  • 8.3 Australia
    • 8.3.1 Market Performance (2008-2015)
    • 8.3.2 Market Segmentation by Class
      • 8.3.2.1 Recombinant Proteins
      • 8.3.2.2 Monoclonal Antibodies
      • 8.3.2.3 Purified Proteins
    • 8.3.3 Performance of Top Players
    • 8.3.4 Market Forecast (2016-2021)
  • 8.4 South Korea
    • 8.4.1 Market Performance (2008-2015)
    • 8.4.2 Market Segmentation by Class
      • 8.4.2.1 Recombinant Proteins
      • 8.4.2.2 Monoclonal Antibodies
      • 8.4.2.3 Purified Proteins
    • 8.4.3 Performance of Top Players
    • 8.4.4 Market Forecast (2016-2021)
  • 8.6 India
    • 8.6.1 Market Performance (2008-2015)
    • 8.6.2 Market Segmentation by Class
      • 8.6.2.1 Recombinant Proteins
      • 8.6.2.2 Monoclonal Antibodies
      • 8.6.2.3 Purified Proteins
    • 8.6.3 Performance of Top Players
    • 8.6.4 Market Forecast (2016-2021)
    • 8.6.5 Market Performance (2008-2015)
    • 8.6.6 Market Segmentation by Class
      • 8.6.6.1 Recombinant Proteins
      • 8.6.6.2 Monoclonal Antibodies
    • 8.6.7 Performance of Top Players
    • 8.6.8 Market Forecast (2016-2021)

9. Global Biopharmaceutical Market: Industry Analysis

  • 9.1 Strengths
    • 9.1.1 High Efficacy and Target Oriented Attack
    • 9.1.2 Strong Potential to Achieve Blockbuster Status
    • 9.1.3 Limited Generic Threat
    • 9.1.4 High Approval Success Rates
  • 9.2 Weaknesses
    • 9.2.1 Inconvenient Drug Delivery
    • 9.2.2 Short Half Lives
    • 9.2.3 Second Line of Therapy
    • 9.2.4 High Cost of Therapy
    • 9.2.5 Incidence of Unfavorable Side Effects
  • 9.3 Opportunities
    • 9.3.1 Diseases with High Unmet Needs
    • 9.3.2 Approval into Additional Indications
    • 9.3.3 Emerging Markets
    • 9.3.4 New Approvals and a Strong Pipeline
  • 9.4 Threats
    • 9.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
    • 9.4.2 Biosimilars
    • 9.4.3 Limited and Conditional Reimbursement
    • 9.4.4 Uncertainties in the Economic Environment

List of Figures

  • Figure 2 1: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 3 1: Complexity of Biopharmaceuticals
  • Figure 3 2: Sources of Biopharmaceuticals
  • Figure 5 1: Global: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 5 2: Global: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 5 3: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2015
  • Figure 5 4: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2021
  • Figure 5 5: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2015
  • Figure 5 6: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 5 8: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2016-2021
  • Figure 5 10: Global: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 5 11: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 5 12: Global: Recombinant Proteins Market Forecast (in Million US$), 2016-2021
  • Figure 5 14: Global: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 5 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 5 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2016-2021
  • Figure 5 18: Global: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 5 19: Global: Purified Proteins Market: Sales Share by Class (in %), 2015
  • Figure 5 20: Global: Purified Proteins Market Forecast (in Million US$), 2016-2021
  • Figure 5 22: Global Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 6 1: US: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 6 2: US: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 6 4: US: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 6 5: US: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 6 6: US: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 6 7: US: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 6 8: US: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 6 9: US: Purified Proteins Market: Sales Share by Class (in %), 2015
  • Figure 6 10: US: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 6 11: US: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 6 13: Canada: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 6 14: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 6 16: Canada: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 6 17: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 6 18: Canada: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 6 19: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 6 20: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 6 21: Canada: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 6 22: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 7 1: Mexico: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 7 2: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 7 4: Mexico: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 7 5: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 7 6: Mexico: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 7 7: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 7 8: Mexico: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 7 9: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 7 10: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 7 11: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 7 12: Brazil: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 7 13: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 7 15: Brazil: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 7 16: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 7 17: Brazil: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 7 18: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 7 19: Brazil: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 7 20: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 7 21: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 7 22: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 7 23: Argentina: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 7 24: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 7 26: Argentina: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 7 27: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 7 28: Argentina: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 7 29: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 7 30: Argentina: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 7 31: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 7 32: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 7 33: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 8 1: Germany: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 8 2: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 8 4: Germany: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 8 5: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 6: Germany: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 8 7: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 8 8: Germany: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 8 9: Germany: Purified Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 10: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 8 11: Germany: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 8 12: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 8 13: France: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 8 14: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 8 16: France: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 8 17: France: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 18: France: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 8 19: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 8 20: France: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 8 21: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 8 22: France: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 8 23: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 8 24: Italy: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 8 25: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 8 27: Italy: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 8 28: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 29: Italy: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 8 30: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 8 31: Italy: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 8 32: Italy: Biopharmaceutical Market: Sales Share of top players (in %), 2015
  • Figure 8 33: Italy: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 8 34: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 8 35: Spain: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 8 36: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 8 38: Spain: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 8 39: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 40: Spain: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 8 41: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 8 42: Spain: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 8 43: Spain: Purified Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 44: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 8 45: Spain: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 8 46: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 8 47: UK: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 8 48: UK: Biopharmaceutical Market, Sales by Class (in Million US$), 2008-2015
  • Figure 8 50: UK: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 8 51: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 52: UK: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 8 53: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 8 54: UK: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 8 55: UK: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 8 56: UK: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 8 57: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 8 58: Russia: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 8 59: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 8 61: Russia: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 8 62: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 63: Russia: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 8 64: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 8 65: Russia: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 8 66: Russia: Purified Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 67: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 8 68: Russia: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 8 69: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 8 70: Turkey: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 8 71: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 8 73: Turkey: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 8 74: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 8 75: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 8 76: Turkey: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 8 77: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 8 78: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 8 79: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 9 1: Japan: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 9 2: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 9 4: Japan: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 9 5: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 6: Japan: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 9 7: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 9 8: Japan: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 9 9: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 9 10: Japan: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 9 11: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 9 12: China: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 9 13: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 9 15: China: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 9 16: China: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 17: China: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 9 18: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 9 19: China: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 9 20: China: Purified Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 21: China: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 9 22: China: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 9 23: China: BiopharmaceuticalMarket Forecast: Sales Share by Class (in %), 2021
  • Figure 9 24: Australia: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 9 25: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 9 27: Australia: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 9 28: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 29: Australia: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 9 30: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 9 31: Australia: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 9 32: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 9 33: Australia: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 9 34: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 9 35: South Korea: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 9 36: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 9 38: South Korea: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 9 39: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 40: South Korea: Monoclonal Antibodies Market (in Million US$), 2006 - 2012
  • Figure 9 41: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2015
  • Figure 9 42: South Korea: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 9 43: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 44: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 9 45: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 9 46: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 9 47: India: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 9 48: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 9 50: India: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 9 51: India: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 52: India: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 9 53: India: Purified Proteins Market (in Million US$), 2008-2015
  • Figure 9 54: India: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 9 55: India: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 9 56: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 9 57: Indonesia: Biopharmaceutical Market (in Million US$), 2008-2015
  • Figure 9 58: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2008-2015
  • Figure 9 60: Indonesia: Recombinant Proteins Market (in Million US$), 2008-2015
  • Figure 9 61: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2015
  • Figure 9 62: Indonesia: Monoclonal Antibodies Market (in Million US$), 2008-2015
  • Figure 9 63: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2015
  • Figure 9 64: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %), 2015
  • Figure 9 65: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2016-2021
  • Figure 9 66: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2021
  • Figure 4 1: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2000& 2012
  • Figure 4 2: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
  • Figure 4 3: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
  • Figure 4 4: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
  • Figure 4 5: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
  • Figure 4 6: Comparison of the Annual Cost of Therapy for Plaque Psoriasis Using Biopharmaceuticals and Small Molecule Drugs (in US$)
  • Figure 4 7: Emerging Biopharmaceutical Market Forecast (in Million US$), 2016& 2021
  • Figure 4 8: Developed Biopharmaceutical Market Forecast (in Million US$), 2016& 2021
  • Figure 4 9: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 1997- 2011
  • Figure 4 10: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in %), 1997 - 2011
  • Figure 4 11: Global: Breakup of Small Molecule Drugs and Biopharmaceuticals in the Total Pharmaceutical Market & Phase III development (%), 2011
  • Figure 4 12: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
  • Figure 4 13: Research and Development Times Taken by Biopharmaceuticals to Reach the Market (in Months), 1982-89,1990-94,1995-99, 2000-04, 2005-09
  • Figure 4 14: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)
  • Figure 4 15: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2011
  • Figure 4 16: Germany, France, Italy, Spain & UK: Epoetin AlfaBiosimilars: Patient Share (in %), 2007-2011
  • Figure 4 17: Germany, France, Italy, Spain & UK: FilgrastimBiosimilars: Patient Share (in %), 2008-2011
  • Figure 4 18: Current Medicare Payer Coverage for Monoclonal Antibodies
  • Figure 4 19: Performance of Biotech Stocks During the Financial Crisis (in %), Jan 2008 to Dec 2008

List of Tables

  • Table 1 1: Global: Biopharmaceutical Market: Definition & Segmentation
  • Table 2 1: Global: Biopharmaceutical Market: SWOT Analysis
  • Table 2 2: Global: Recombinant Proteins Market Forecast: Sales by Class (in Million US$),
  • Table 2 3: Global: Monoclonal Antibodies Market Forecast: Sales by Class (In Million US$), 2016& 2021
  • Table 2 4: Global: Purified Proteins Market Forecast: Sales by Class (In Million US$), 2016& 2021
  • Table 2 5: Global: Biopharmaceutical Market Forecast: Sales by Region (In Million US$), 2016& 2021
  • Table 3 1: Differences Between Small Molecule Drugs & Biopharmaceuticals
  • Table 3 2: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
  • Table 5 1: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2008-2015
  • Table 5 2: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2016-2021
  • Table 5 3: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2015
  • Table 5 4: Global: Contribution of Various Classes to Total Biopharmaceutical Growth (in Million US$), 2016-2021
  • Table 5 13: Global: Purified Proteins Market: Sales by Class (in Million US$), 2008-2015
  • Table 5 19: Global: Biopharmaceutical Market Forecast: Sales of Top Biopharmaceuticals (in Million US$), 2015 & 2021
  • Table 7 12: Brazil: Purified Proteins Market: Sales by Class (in Million US$), 2008-2015
  • Table 7 14: Brazil: Biopharmaceutical Market: Sales of Top Players (in Million US$), 2008-2015
  • Table 4 1: Global: Top Ten Selling Drugs (Based on Origin), 2000
  • Table 4 2: Global: Top Ten Selling Drugs (Based on Origin), 2012
  • Table 4 4: Mode of Administration of Popular Biotech Drugs
  • Table 4 5: FDA: Total Number of Biopharmaceutical Approvals in 2011
  • Table 4 6: US and European Statistics of Branded Biopharmaceutical Products Facing Biosimilar Threat (in Million US$), 2011
Back to Top